Sarepta Therapeutics (NASDAQ: SRPT) has recently received a number of price target changes and ratings updates:
- 7/1/2024 – Sarepta Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $205.00 price target on the stock.
- 6/27/2024 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $235.00 price target on the stock.
- 6/26/2024 – Sarepta Therapeutics was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $176.00 price target on the stock, up previously from $172.00.
- 6/24/2024 – Sarepta Therapeutics had its price target raised by analysts at SVB Leerink LLC from $165.00 to $230.00. They now have an “outperform” rating on the stock.
- 6/24/2024 – Sarepta Therapeutics had its price target raised by analysts at BMO Capital Markets from $170.00 to $200.00. They now have an “outperform” rating on the stock.
- 6/24/2024 – Sarepta Therapeutics had its price target raised by analysts at Evercore ISI from $139.00 to $185.00. They now have an “in-line” rating on the stock.
- 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Royal Bank of Canada from $142.00 to $182.00. They now have a “sector perform” rating on the stock.
- 6/21/2024 – Sarepta Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $157.00 price target on the stock.
- 6/21/2024 – Sarepta Therapeutics had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $165.00 price target on the stock.
- 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Barclays PLC from $185.00 to $226.00. They now have an “overweight” rating on the stock.
- 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Robert W. Baird from $170.00 to $200.00. They now have an “outperform” rating on the stock.
- 6/21/2024 – Sarepta Therapeutics had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.
- 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Needham & Company LLC from $166.00 to $235.00. They now have a “buy” rating on the stock.
- 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Bank of America Co. from $166.00 to $213.00. They now have a “buy” rating on the stock.
- 6/14/2024 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $170.00 price target on the stock.
- 5/31/2024 – Sarepta Therapeutics is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $157.00 price target on the stock.
- 5/28/2024 – Sarepta Therapeutics had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $142.00 price target on the stock, down previously from $157.00.
- 5/20/2024 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $166.00 price target on the stock.
- 5/17/2024 – Sarepta Therapeutics had its price target raised by analysts at Mizuho from $145.00 to $179.00. They now have a “buy” rating on the stock.
- 5/14/2024 – Sarepta Therapeutics was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $180.00 price target on the stock.
Sarepta Therapeutics Trading Down 0.7 %
NASDAQ:SRPT opened at $153.11 on Thursday. The stock has a market cap of $14.47 billion, a price-to-earnings ratio of 1,391.91 and a beta of 0.89. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The business has a fifty day moving average of $131.86 and a 200-day moving average of $123.74.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. Sarepta Therapeutics’s quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter last year, the company earned ($1.44) EPS. Equities analysts predict that Sarepta Therapeutics, Inc. will post 3.71 earnings per share for the current year.
Insider Buying and Selling
Institutional Investors Weigh In On Sarepta Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Principal Securities Inc. acquired a new position in Sarepta Therapeutics in the 4th quarter worth approximately $26,000. Mather Group LLC. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at $28,000. Riggs Asset Managment Co. Inc. raised its position in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the period. New Covenant Trust Company N.A. purchased a new stake in Sarepta Therapeutics in the 1st quarter worth about $32,000. Finally, GAMMA Investing LLC boosted its position in Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 87 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Featured Stories
- Five stocks we like better than Sarepta Therapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Most active stocks: Dollar volume vs share volume
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- How to Invest in Blue Chip Stocks
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.